mRNA-4157 Plus Pembrolizumab Under Further Investigation in Phase 3 Trial in High-Risk Melanoma

Source: OncLive, July 2023

The combination of mRNA-4157 (V940) and pembrolizumab (Keytruda) will be further evaluated as an adjuvant treatment option for patients with resected, high-risk, stage IIB to IV melanoma in the phase 3 V940-001 trial (NCT05933577).

The global, randomized, double-blind, placebo-controlled study will evaluate mRNA-4157 plus pembrolizumab vs placebo plus pembrolizumab in approximately 1089 patients with high-risk, stage IIB to IV melanoma following complete resection. Enrollment for the trial has commenced, with the first patients enrolling in Australia.

“As we continue our efforts to advance novel treatment options for patients with high-risk, stage IIB to IV melanoma, the initiation of the V940-001 phase 3 trial represents an important step forward in these efforts and our study of individualized neoantigen therapy,” Marjorie Green, MD, senior vice president and head of Late-Stage Oncology, Global Clinical Development, at Merck Research Laboratories, stated in a news release. “We look forward to continuing to collaborate with Moderna to evaluate this promising new approach with mRNA-4157, while also building on a standard of care laid by [pembrolizumab].”